[1] Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer[J]. Lancet, 2021,398(10299):535-554.
[2] Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, and prevention[J]. Clin Chest Med, 2020,41(1):1-24.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[4] Torre LA, Siegel RL, Jemal A. Lung Cancer
Statistics[J]. Adv Exp Med Biol, 2016, 893:1-19.
[5] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5):584-590.
[6] 秦娜,马红霞,靳光付,等. 肺癌流行病学研究年度进展2022[J]. 中华医学杂志, 2023,103(14):1068-1073.
[7] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
[8] NGM.General information[EB/OL]. (2016-02-29)[2023-10-12]. https://ngm-cancer.com/en/general-information/.
[9] NGM.Driver mutations in lung
cancer[EB/OL]. (2016-03-07)[2023-10-12]. https://ngm-cancer.com/en/driver-mutations/.
[10] NGM. Introduction to the Lung
Cancer Group Cologne[EB/OL]. (2016-03-07)[2023-10-12]. https://www.lungcancergroup.de/en/who-we-are/.
[11] Lung Cancer Group Cologne.
Molecular pathology[EB/OL]. (2018-01-26)[2023-10-12]. https://www.lungcancergroup.de/en/molecularpathology/.
[12] NGM. Aim of the NGM[EB/OL]. (2016-03-07)[2023-10-12]. https://ngm-cancer.com/en/the-network/aims/.
[13] NGM.NGM Publications[EB/OL]. (2018-07-18)[2023-10-12].https://ngm-cancer.com/en/the-network/publications/.
[14] Frank R, Scheffler M, Merkelbach-Bruse S, et al. Clinical and
pathological characteristics of KEAP1- and NFE2L2-mutated non-small cell lung carcinoma (NSCLC) [J]. Clin Cancer Res, 2018, 24(13): 3087-3096.
[15] Scheffler M, Ihle MA, Hein R, et al. K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways[J]. J Thorac Oncol, 2019,14(4): 606-616.
[16] Castiglione R, Alidousty C, Holz B, et al. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences
and analogies[J]. Mod Pathol, 2019, 32(5):627-638.
[17] Fassunke J, Müller F, Keul M, et al. Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding
characteristics of second-generation EGFR inhibitors[J]. Nat Commun, 2018, 9(1): 4655.
[18] NGM. Funding of NGM[EB/OL]. (2016-03-01)[2023-10-12]. https://ngm-cancer.com/en/the-network/funding/.
[19] NGM. The Network[EB/OL]. (2016-03-01)[2023-10-12]. https://ngm-cancer.com/en/the-network/.
[20] ICPerMed.1st Best Practice
Example of Personalised Medicine Research & Implementation-From Basic Research to the Patient[EB/OL]. [2023-10-12]. https://www.icpermed.eu/en/526.php.
[21] nNGM. About the nNGM[EB/OL].(2021-09-16)[2023-10-12]. https://nngm.de/en/about-the-nngm/.
[22] Glaser M, Rasokat A, Prang D, et al. Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients[J]. Lung Cancer, 2023,184:107344.
[23] nNGM. Team of nNGM[EB/OL]. (2016-03-01)[2023-10-12]. https://ngm-cancer.com/en/the-network/our-team/.
[24] nNGM. nNGM Centers[EB/OL]. (2019-04-10)[2023-10-12]. https://nngm.de/en/centers/.
[25] 国家卫生健康委, 国家中医药局,
国家疾控局. 关于印发全国医疗服务项目技术规范(2023年版)的通知[EB/OL]. (2023-09-28)[2023-10-12].http://www.nhc.gov.cn/caiwusi/s7785t/202309/914aec9618944ee2b36621d33517e576.shtml.
[26] 中国临床肿瘤学会肿瘤标志物专家委员会, 中国肿瘤驱动基因分析联盟. 二代测序技术在肿瘤精准医学诊断中的应用专家共识[J].中华医学杂志, 2018, 98(26):2057-2065.
[27] 二代测序临床报告解读肿瘤学专家组.肿瘤二代测序临床报告解读共识[J].循证医学,2022,22(2):65-79.
|